Skip to main content
Premium Trial:

Request an Annual Quote

NIDA Seeks Small Businesses with PGx Expertise to Guide Research on Rx Addiction

Premium

Originally published July 26.

The National Institute on Drug Abuse has issued a notice to survey whether any small businesses have the expertise to provide pharmacogenetic research support services for studies on drug addiction.

In a "sources sought" notice issued July 22, NIDA explained that its medications development program is looking for "qualified businesses or universities to coordinate the genetics component of clinical trials focused on drug addiction treatment."

Small businesses with the capability to demonstrate in-depth knowledge and expertise in the overall management of a clinical research center — including DNA and RNA analyses on blood samples collected in the studies; pharmacogenetic interpretation of patients' responses to drugs; identification of biomarkers of addiction; pharmacokinetic analyses; data interpretation; and writing high quality reports — should send NIDA a statement about their qualifications by Aug. 10.

Interested applicants will need to be knowledgeable of genotyping using Affymetrix's GeneChip mapping 500 array sets and expression analyses with Affy's Human Genome U-133 Plus 2.0 arrays.

NIDA said it is seeking information on similar projects that candidate companies have conducted previously, the professional qualifications and experience of company personnel; and details on any experience in the field of drug abuse research.

Furthermore, the notice explains that NIDA is not issuing a notice for proposals. "This notice is for information and planning purposes only and does not commit the government to any contractual agreement," NIDA said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more